A r t i c l e s The Cancer Genome Atlas (TCGA) and other large-scale genome sequencing projects are providing growing catalogs of somatic and epigenetic alterations in cancer [1] [2] [3] [4] . An ongoing challenge, however, is how to effectively identify subsets of functionally relevant lesions and potential therapeutic targets 5, 6 . These 'driver' lesions, in synergistic combinations, are responsible for the generation and maintenance of the oncogenic state and may determine the characteristics of each tumor or tumor type. The identification of such drivers is complicated by genomic instability, which increases the number of genomic alterations, including low-penetrance events, with uncertain functional roles.
Genome-wide functional studies of cancer cell lines and tumors have proven useful in identifying associations between gene dependencies and genomic abnormalities [7] [8] [9] [10] [11] . Associating recurrent genomic abnormalities with their matching therapeutic agent is a common strategy under the 'oncogene addiction' paradigm. However, the challenge of effectively mapping molecular alterations to pathway activity and drug response can be difficult, as those relationships are not one to one. Indeed, some driver mutations only partially predict drug response because of functional heterogeneity and the rise of resistance mechanisms.
One way to address these difficulties is to systematically explore the landscape of mutually exclusive genomic abnormalities along so called functional axes that represent the activation of oncogenic pathways or sensitivity to genetic or chemical perturbations. The use of appropriate functional profiles is important because the complementary nature of genomic alterations is only clearly delineated in the right context. For example, when the relevant oncogenic programs, and other synergies such as immune or stress responses, are coactivated to drive or maintain the oncogenic state.
We developed REVEALER (repeated evaluation of variables conditional entropy and redundancy), a method for identifying groups of genomic alterations that together associate with a functional activation, gene dependency or drug response profile. The combination of these alterations explains a larger fraction of samples displaying functional target activation or sensitivity than any individual alteration characterizing genomic alterations in cancer by complementary functional associations Systematic efforts to sequence the cancer genome have identified large numbers of mutations and copy number alterations in human cancers. However, elucidating the functional consequences of these variants, and their interactions to drive or maintain oncogenic states, remains a challenge in cancer research. We developed REVEALER, a computational method that identifies combinations of mutually exclusive genomic alterations correlated with functional phenotypes, such as the activation or gene dependency of oncogenic pathways or sensitivity to a drug treatment. We used REVEALER to uncover complementary genomic alterations associated with the transcriptional activation of b-catenin and NRF2, MEK-inhibitor sensitivity, and KRAS dependency. REVEALER successfully identified both known and new associations, demonstrating the power of combining functional profiles with extensive characterization of genomic alterations in cancer genomes.
A r t i c l e s considered in isolation. REVEALER can be applied to a wide variety of problems and allows prior relevant background knowledge to be incorporated into the model. We found that REVEALER could be used to identify genomic features associated with functional cancer phenotypes, demonstrating its higher sensitivity and specificity compared with other model-selection methods.
RESULTS

REVEALER overview
The optimal execution of REVEALER requires three inputs: a functional 'target' profile for individual samples across a given dataset, a dataset containing a comprehensive collection of genomic 'features' for the same samples and an optional 'seed' feature with which to initialize the search. The target profile is a readout from quantitative measurements, including, for example, gene expression, pathway activation, gene dependency or drug response. Ideally, the seed is a feature that has a known effect on the target profile. REVEALER starts by measuring the degree of association between the target and seed feature using a re-scaled mutual information metric that we call the information coefficient (IC; Fig. 1a) . The IC is a non-linear correlation coefficient that takes values between 1 (perfect match) and -1 (perfect anti-match). One key distinguishing feature of REVEALER is the ability to identify features based on both target profile and seed. Features that match the target profile, but are correlated with the seed, are penalized, whereas features that associate with the target and are also complementary to the seed are scored higher. In this way, only genomic features that explain activation or sensitivity in the target profile that is not already accounted for will be included in the model. REVEALER achieves this by computing the conditional mutual information of the target profile and each feature, conditioned on the seed feature. We refer to this as the conditional information coefficient (CIC) (Fig. 1b) . REVEALER then iterates this process ( Fig. 1c) .
Alterations associated with b-catenin activation We first used REVEALER to identify genomic features associated with the oncogenic activation of β-catenin 12 . In Figure 2a , the target t is a β-catenin activation TCF4 reporter 13 assayed across 83 cancer cell lines whose mutations and copy number profiles have previously been reported 14 . The seed feature, s 0 , corresponding to activating mutations in β-catenin (S33, S34, S37, T45, T41), is also shown. The seed feature associated strongly with the target (IC = 0.44) with all of the β-catenin mutations located where the reporter readout was high, consistent with the known activating role for these events. However, about half of the samples with high β-catenin activation could not be explained by alterations in β-catenin. Thus, we used REVEALER to find additional genomic features from a large set of candidates to explain the activation of the target profile.
The top-scoring genomic feature of the first REVEALER iteration (CIC=0.49) was APC mutations ( Fig. 2a) . REVEALER found this specific alteration from 17,721 feature candidates consisting of 671 mutations and 17,050 amplifications and deletions ( Supplementary Fig. 1a ). These were generated after filtering out low-and high-frequency features from an initial set of 48,270 features. APC mutations are known to be associated with an uncontrolled stabilization and transcriptional activation of β-catenin 15 and are mutually exclusive with β-catenin mutations. Combining β-catenin and APC mutations to obtain a summary feature increased the IC with the target to 0.61 ( Fig. 2a ). REVEALER then proceeded to a second iteration and found the amplification of chr13q33 (ITGBL1_AMP) as the top scoring feature (CIC= 0.49; Fig. 2a ). Several other features in the same region, chr13q11-34, also attained almost the same CIC (Supplementary Fig. 2a ). Recurrent amplifications in 13q are indeed common in colon cancer, and, notably, one of our previous studies identified CDK8 in chr13q12.13 as a colon oncogene that regulates β-catenin activity 16 . Attempts to perform a third iteration failed to find any feature that would increase the IC Figs. 1 and 2) . In addition to finding the best scoring abnormalities at every iteration, REVEALER also clustered them to facilitate the identification of alternative or 'second-best' hits ( Supplementary Figs. 1b and 2b) .
We also investigated whether these features associate with shRNA β-catenin dependence in cancer cell lines. The samples harboring REVEALER's features indeed displayed a much higher degree of β-catenin dependency (P values: 0.0005, 0.0001 and 0.0009, respectively) and were highly complementary to each other (Fig. 2b) . This significant mutual exclusivity and association with both transcriptional and dependency target profiles provides strong evidence that these alterations indeed activate β-catenin.
To investigate REVEALER's results robustness, we randomly subsample 80% of the samples, re-ran REVEALER, and found that APC mutations and the 13q-12-34 amplicon re-appeared in eight of ten runs, suggesting that these results are reasonably robust.
Transcriptional NRF2/NFE2L2 activation in lung cancer
We found that REVEALER can also be used with a combined seed feature. The transcription factor NRF2 (NFE2L2) induces a cytoprotective response to oxidative stresses and its mutations confer constitutive activation in cancer 17 . We generated a target profile using the singlesample GSEA 8 scores of NRF2-driven genes 18 across 182 lung cancer cell lines from the Broad-Novartis Cancer Cell Line Encyclopedia, hereafter referred to as CCLE 14 . We selected lung cancer cell lines as a result of the higher frequency of NFE2L2 alterations 19, 20 , and used both NFE2L2 mutations and amplifications as a seed (Fig. 3a) . REVEALER merged multiple seeds (logical OR function) to produce a single summary seed. The input genomic features consisted of a set of 32,154 alterations (991 mutations and 31,253 amplification and deletions after filtering from an original set of 48,270).
The first REVEALER iteration yielded KEAP1 mutations, which are established direct mediators of NRF2 and its targets 21 ( Fig. 3a and Supplementary Fig. 3 ). The second iteration yielded features encompassing amplification of chr15q22/26 (OR4F13P_AMP; Fig. 3a and Supplementary Fig. 4 ). Besides these two, no other features improved the match with the target. Of special interest in this amplicon was NOX5 (NADPH oxidase 5), as its α and β isoforms have been implicated in the production of extracellular superoxide, H 2 O 2 , or other reactive oxygen species (ROS) [22] [23] [24] .
To experimentally assess whether NOX5 indeed regulates NRF2 transcriptional activity, we used an antioxidant response element (ARE) luciferase reporter as readout of the NRF2 pathway 25 . We cotransfected ARE-driven luciferase reporter construct with NOX5, NRF2 (positive control), and LacZ (negative control) open-reading frame (ORFs) constructs. We found that NRF2 and NOX5 ORF constructs led to significant increases (NOX5 versus LacZ, *P > 0.01; NRF2 versus LacZ, **P > 0.001) in the ARE-driven luciferase activity relative to LacZ, or no vector, indicating that NOX5 expression indeed regulates ARE (Fig. 3b) . To test whether these results comport with biological behavior in vivo, we examined a TCGA lung cancer dataset 26 and found that these genomic features were enriched in tumors with higher NRF2 activation, suggesting that REVEALER's results generalize to tumors ( Supplementary Fig. 5 ). We found that REVEALER could be used for de novo discovery without a seed and with a drug sensitivity target. MEK (MAP2K1), a member of the MAPK signaling pathway, is constitutively activated as a result of oncogenic mutations in, for example, BRAF, RAS and MEK 1 (ref. 27) . As a target, we used the sensitivity profile to the MEK inhibitor PD-0325901 (ref. 28 ) in 493 cancer cell lines from the CCLE. Given that MEK itself is rarely mutated, we ran REVEALER without a seed. The first iteration of REVEALER yielded BRAF mutations as the top-scoring feature ( Fig. 4 and Supplementary Fig. 6 ). The next two iterations yielded mutations in KRAS and NRAS. These three genes are well-known oncogenic activators of MAPK signaling, and their combination explained a large fraction of PD-0325901 sensitive samples in the CCLE ( Fig. 4 and Supplementary Figs. 7 and 8) .
KRAS dependency
REVEALER can be used with a gene-dependency target. The high frequency of KRAS mutations highlights its importance as a major oncogene. In addition to studies linking KRAS mutations with dependency 29 , there is growing evidence for KRAS wild-type states that are also KRAS dependent 8, 9 . Consistent with these findings, our examination of KRAS dependency profile across cancer cell lines 30 revealed that, although KRAS dependency associated with KRAS mutation status (IC = −0.41), a substantial number of wild-type samples were also dependent on KRAS. We used REVEALER to assess whether any other genomic alteration besides KRAS mutation might account for these unexplained KRAS dependencies. As a target, we used the shRNA KRAS dependency score and KRAS mutations as seed ( Fig. 5a) . Notably, REVEALER found a copy number gain (CNG) in chr8q23-4 (NSMCE2_AMP) as the top-scoring feature in the first iteration ( Fig. 5a and Supplementary Fig. 9 ). This feature was followed by amplifications in chr9p21 and chr12p12 (KRAS locus) and deletions in chr9q12 as potentially complementary alterations with lesser incremental benefit ( Fig. 5a and Supplementary Figs. 10-12). These features together explain the majority of the KRASdependent cell lines: 30 of the top 35 samples with higher KRAS dependency ( Fig. 5a) .
Alterations in chr8q23-24 are frequent events in cancer 31 , and the REVEALER finding corresponded to a broad region of chr8q23-24 (chr8q24 gain) instead of the more specific focal MYC amplification (MYC amplification; Fig. 5b ). To assess differences in KRAS dependence, we grouped cell lines on the basis of MYC amplification, chr8q24 gain, KRAS mutations or none of the above. We found statistically significant differences between cells that harbored chr8q24 gain and cells that either had MYC amplification (**P = 0.0064 ) or other genotypes (**P = 0.0012) ( Fig. 5c) . Given that both events are centromeric with respect to, and potentially target, MYC itself, we studied the differences in MYC expression between these events. MYC amplified cell lines had significantly higher expression of MYC (**P = 0.0039) than cell lines with the 8q24 gain ( Fig. 5d) , which perhaps can be explained by high copy number value of MYC amplification region (data not shown). This is consistent with previous studies showing that tumors with low MYC expression display increased dependence on KRAS 32 .
To further validate these findings, we selected an independent panel of NSCLC cell lines with either mutations in KRAS, chr8q24 gain or controls, and assayed them for relative viability following suppression of KRAS (Fig. 5e ). shRNAs validated against KRAS 8,9 were used to assess whether 8q24 gain predicts sensitivity to KRAS suppression. As expected, cells with mutant KRAS status were highly dependent on KRAS. Consistent with previous observations 8, 33 , we found that cells that did not have alterations in KRAS or chr8q24 were less dependent on KRAS; however, cells that harbored 8q24 gain were more sensitive to KRAS suppression, suggesting that these samples indeed require KRAS for their survival. 
A r t i c l e s
Comparisons with other methods: simulated data analysis We investigated how effective the CIC metric used by REVEALER is at finding a known complementary feature in controlled circumstances, where the ground truth is known. We also compared the CIC with alternative approaches, including the partial correlation coefficient, the ElasticNet 34 and mRMR 35 . We generated 5,000 simulated data instances of target, seed and complementary-feature (the signal) using probabilistic models parameterized to fit to the empirical data using skew-t distributions and random sampling. We also generated a set of 2,000 random features (the noise) ( Supplementary Figs. 13 and  14) . We used each method to find the correct complementary feature in each instance and evaluated the results using receiving operating characteristics (ROC) curves, which we could estimate because we knew the correct complementary feature in each case. We found that the CIC was the most sensitive at finding the correct complementary feature and attained an area under ROC equal to 0.872, compared with 0.674 for partial correlation, 0.633 for ElasticNet and 0.672 for mRMR ( Fig. 6a and Supplementary Fig. 14) .
Comparisons with other methods: real genomic data Methods to search for complementary genomic alterations [36] [37] [38] [39] [40] [41] [42] or general non-redundant features have been proposed 34, 35, 43 . However, REVEALER differs from these methods in several aspects. First, it incorporates three inputs: a target profile, a features dataset and a seed feature(s). Second, it uses a sequential search process in which the features found in subsequent iterations are influenced by the choice of features in early iterations. Finally, REVEALER uses the conditional differential mutual information. These distinctions make it difficult to directly compare REVEALER with other methods; however, if one restricts the comparison to cases with no seed, REVEALER can be compared with other methods such as the ElasticNet 34 and Dendrix 41 . Figure 5 REVEALER results for KRAS-dependency. (a) The target profile was the relative KRAS-dependence score in 100 cancer cell lines. The seed feature was the mutation status of KRAS, a well-known cause of activation, and the genomic features matrix represented mutations and copy number alterations in the same cell lines. REVEALER identified a copy number gain (CNG) across a region on chromosome 8q23-24 as the most complementary genomic alteration to KRAS mutation to explain KRAS dependency. Other features such as amplifications in chr9p21, and chr12p12 and deletions in chr9q12 were also identified, but with lesser incremental benefit. (b) Pattern of copy number changes in cancer cells that have gain in 8q23-24 showed that copy number changes centromeric to MYC had two distinct patterns. Red indicates regions of chromosomal gain (log 2 ratio > 0.6). (c) Dot plot of relative KRAS dependence across cell lines with various genotypes (x axis). Differential KRAS dependence between cells were examined between cells with copy number gain on 8q23-24 relative to cells with other genotype (Student's t-test with Welch's correction, **P = 0.0064, **P = 0.0012). (d) Dot plot of relative MYC mRNA expression across cell lines with various genotypes (x axis). Differential MYC mRNA levels were assessed between cells with copy number gain on 8q23-24 versus MYC amplification (Student's t test with Welch's correction, **P = 0.0039). (e) Validation of KRAS dependence in non-small cell lung cancer cells with indicated genotypic status. Cancer cells that harbored 8q23-24 gain from the CCLE were chosen and their relative KRAS dependence was assessed for cells that either had mutations in KRAS or those that harbored 8q23-24 alteration (KRAS mutant cells: NCI-H2009, NCI-H1944, A549, NCI-H1792), 8q23-24 gain (NCI-H2110, NCI-H1781, NCI-H1648, NCI-H2126, NCI-H2342) or others (NCI-H28 NCI-H1437, NCI-H2228). Relative viability was assessed using CellTiter-Glo assay (Promega) and by normalizing the luminescence values of shKRAS infected cells with shLuciferase controls 7 d post-infection.
npg
A r t i c l e s
We compared REVALER to the ElasticNet 34 and Dendrix 41 using the data from the four examples above without seeds to provide insights into the characteristics of each method and delineate their potential suitability to different problem settings.
We summarized the results using the target association score, the absolute value of the IC of a summary feature consisting of the combination of all the top selected features, and the feature complementarity index, 1 minus the average IC across pairs of features ( Table 1 and Fig. 6b ). Several of the features found by the ElasticNet overlapped with those found by REVEALER, suggesting that strong feature-target associations are retrieved by both methods ( Table 1) Table 1 (IC metric), and the corresponding results using the square error metric instead of the IC. Each row corresponds to one method's results. The first method is REVEALER as described in the examples in the main text, the second is REVEALER without the seed, the third is the ElasticNet and the fourth is Dendrix. The quantities shown are the target association score, the absolute value of the IC of the summary feature consisting of the combination of all the top selected features, and the feature complementarity index, 1 minus the average IC across pairs of features. A higher complementarity index means that the features are more mutually exclusive. *Confirmed experimentally (gene NOX5, this study). # KRAS locus. † Potentially representing loss of wild-type KRAS. npg A r t i c l e s selected by the ElasticNet, although correlated with the target profile, were less complementary with each other than the ones selected by REVEALER (Fig. 6b) . This is likely a consequence of ElasticNet's cost function 34 , which favors fitting the target and selecting features with low correlation with each other, but not necessarily mutual exclusivity. Dendrix produced rather different sets of features compared with the other methods (Table 1 and Supplementary Fig. 15 ) and performed a more comprehensive search of feature complementarity without using the sample-per-sample target. As a consequence, Dendrix appeared to find features with high complementarity to each other, but somewhat less association with the target (Supplementary Fig. 15 ).
DISCUSSION
We found that REVEALER can be used to map genomic alterations to their relevant functional profiles. We identified APC mutations and amplification of 13q33 as alternative causes of β-catenin activation, and KEAP1 mutations and amplification of chr15q22/26 as alternative causes of NRF2 activation. We also uncovered associations between BRAF, KRAS and NRAS mutations and MEK-inhibition sensitivity. Furthermore, we validated the role of NOX5 in NRF2 activation and highlighted the association between the chr8q23-4 amplicon and KRAS dependency.
The use of mutual information for estimating genomic feature association is not new [44] [45] [46] . However, in contrast with previous approaches, REVEALER makes use of conditional mutual information based on continuous distributions and avoids the need for discretization and other simplifying assumptions. The simulated benchmark showed that REVEALER can identify a complementary feature reasonably well when its CIC is above 0.30 for a wide range of IC values between target and seed The results also show that the conditional mutual information is more sensitive than the partial correlation, and other selection methods, to discriminate subtler relationships between genomic features.
The comparative results across methods ( Table 1 and Supplementary  Fig. 15 ) suggest that REVEALER strikes a good balance between weighting the features' complementarity and their association with the target. REVEALER is particularly well suited in cases in which there is an accurate sample-per-sample functional profile representing a biological state of interest, prior information to guide the choice of seed(s) and a comprehensive characterization of genomic abnormalities.
The differences between approaches are likely produced by the different emphasis of each algorithm. The ElasticNet emphasizes finding uncorrelated features that primarily predict the target and are not strictly restricted to be complementary. This method is well suited for cases where matching the target profile is more important than strict feature complementarity. Dendrix is more suited to finding multiple sets of features that are highly complementary in a subset of samples with less emphasis on fitting the target. These complementary approaches emphasize different aspects of feature selection and have potential applicability depending on the problem setting.
Data availability REVEALER is available as a standalone R program (library, examples and results) as Supplementary Code and also in GenePattern (http://www.genepattern.org/). The datasets are described in detail in the Datasets and pre-processing and Target datasets preparation sections in Online Methods. The target profiles for each example are provided as part of the Supplementary Code. The features dataset is available from the CCLE web site (http://www.broadinstitute.org/ ccle, listed as 'binary calls for copy number and mutation data' in the browse/data section).
METHODS
Methods and any associated references are available in the online version of the paper.
Note: Any Supplementary Information and Source Data files are available in the online version of the paper.
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ONLINE METHODS
Detailed method description. REVEALER method (for pictorial description see Fig. 1c ).
Procedure: REVEALER (t, s 0 , F, max iter, n top hits) Inputs: t = target, a continuous functional response of interest. s 0 = starting seed, one or more binary features(s) representing known "causes" of activation or features associated with the target. F = matrix of features, a collection of binary present/absent features, typically representing genome-wide alterations (mutations, amplifications/deletions).
max iter = maximum number of iterations to perform n top hits = top n hits to display at each iteration.
Step 1: Sort t in decreasing order (same order for s 0 and the columns of F).
Step 2: Pre-process F, optionally filter genomic features that are too infrequent or too frequent and/or consolidate genomic abnormalities, that is, amplification or deletions that are identical or near identical up to a given Hamming distance threshold.
Step 3: Set 1st summary feature to the seed feature (s o ). Multiple seed features are reduced to one by combining (OR-ing) them.
Step 4: Iterate max iter times:
1. sort(F) by rows (x i ) in decreasing order according to CIC(t, x i | s k-1 ). 2. Identify top hit x k and display n top hits as a heat map. 3. Cluster and display pattern of n top hits using Non-Negative Matrix factorization for several value of k (number of clusters) choose k using the cophenetic coefficient.
Compute complementary nominal p-values and False Discovery Rates (FDR)
using a permutation test on the target profile to generate a null dist. 5. Compute summary feature s k = OR(s k-1 , x k ). 6. Compute the Information Coefficient IC(t, s k ) between the new summary feature s k and the target t.
Output: n top hits at each iteration.
Final heat map summary of seed, top features and summary features at each iteration, and their associations with the target IC(t, s k ).
At every iteration the permutation test and its associated P values and FDRs are not used directly by REVEALER, but provide a complementary assessment of significance.
REVEALER information coefficients. REVEALER's use of mutual and conditional mutual information has several advantages over the correlation coefficient [47] [48] [49] [50] [51] . The mutual information 52, 53 , I(t,s), is a function of the ratio of joint and marginal probabilities
I t s P t s P t s P t P s dtds ( , )
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= ∫∫
REVEALER rescales the mutual information making it easier to interpret and lie in the range [−1, 1], in analogy with the correlation coefficient, using the relationship between mutual information and correlation for Gaussian variables 54 : I(t, s) = −0.5 log(1 − ρ 2 (t, s)). The information coefficient (IC) 47, 48 is defined as
IC t s sign t s I t s ( , )
( ( , )) ( exp( ( , )) = − − r 1 2
where we add 'directionality' using the sign of the correlation coefficient between the variables. The relevant information coefficient is that between the target t and each summary feature IC(t, s k ). Notice that, as the target is typically a continuous variable and the summary variable binary, the mutual information between them becomes the Jensen-Shannon divergence between the two continuous target distributions indexed by the summary variable variable 55 .
For the REVEALER iterations we also require the use of the conditional mutual information 52 , (1)
(2)
(3)
Estimating these quantities involves the computation empirical probability density distributions for the relevant variables using kernel density estimators 56 (R packages MASS 57 , misc3d 58 , and bcv 57, 59 ). The pre-processing of feature and target datasets, the clustering of abnormalities and experimental assays are described in detail below.
The target association score shown in Table 1 and Figure 6b is the IC of the summary feature against the target profile. The feature complementarity index is computed as one minus the average of the IC scores of all pairs of features in the results set.
Datasets and pre-processing. The features dataset (CCLE_MUT_CNA_ AMP_DEL_0.70_2fold.MC.gct) used in all the examples as the input feature dataset is derived from the original Cancer Cell Line Encyclopedia (CCLE) mutation and copy number datasets. This dataset was introduced previously 14 (http://www.broadinstitute.org/ccle). It contains 1,030 cancer cell line samples representing over 20 different tissue types and 48,270 binary entries for the mutation, amplification and deletion status of many genes.
Mutation entries (MUT). The specific entries for the mutation status of 1,638 genes are labeled: gene symbol_MUT and correspond to the mutations status (1=present, 0=absent) as determined by the hybrid capture assay described previously 14 .
Copy number entries: amplification (AMP) and deletions (DEL) . There are also 23,315 amplifications and 23,315 deletions entries labeled gene_symbol_ AMP and gene_symbol_DEL, respectively. These are computed from the original copy number 'per gene' CCLE file using a threshold of 0.70 (approximately a twofold change in log scale) in such way that a copy number above 0.70 is defined as an amplification (gene_symbol_AMP = 1), and a copy number under -0.70 (approximately a 1/2-fold change in log scale) is defined as a deletion (gene_symbol_DEL = 1). The original dataset is described elsewhere 14 .
Manually curated abnormalities. A few manually curated entries (labeled with the suffix MC (manually curated) were added to the dataset to represent more accurately a few selected abnormalities including APC.MC_MUT, CTNNB1.MC_MUT, NFE2L2.MC_MUT, KEAP1.MC_MUT, BRAF.MC_ MUT, NRAS.MC_MUT, BRAF.V600E_MUT and KRAS.G12-13_MUT. To run REVEALER we will match this input features dataset sample per sample to different target profiles (see detail definition below).
Filtering out low/high frequency features. We filtered mutation and copy number features with low/high frequency by counting the number of non-zero entries in each feature and excluding those features where this count is less than a low count threshold, or greater than a high count threshold. low-count thresholds were defined as 3 in all four examples. High count thresholds were defined as 50 in examples 1, 2 and 4, and 100 in example 3. The high-count threshold is larger in example 3 because it uses a larger dataset.
Target datasets preparation. The target used in REVEALER can be a readout from any functional assay including level of individual transcripts from gene expression profile, gene set enrichment scores, response to treatment with drugs or dependency profile from RNAi, a quantitative phenotypes or any physical cellular characteristics such as size etc. For the examples used in this paper the target datasets were obtained as described below. Example 1. This dataset (CTNNB1_transcriptional_reporter.gct) consists of measurements of a β-catenin/TCF4 reporter made as part of a previous study 13 . The validation dataset used in this example (CTNNB1_Essentiality_profile. gct) contains a β-catenin shRNA dependency profile in 209 cell lines from release 2.4.2 of the Achilles dataset 9 (Achilles_QC_v2.4.2.rnai.Gs.gct) available at http://www.broadinstitute.org/achilles. The 'per gene' essentiality profiles are provides as part of the official Achilles release and obtained using the ATARiS (analytic technique for assessment of RNAi by similarity) 30 algorithm.
Example 2. This target dataset was generated using per-sample single-sample GSEA NRF2 enrichment profiles for each of 182 lung cell lines from the Broad-Novartis CCLE 14 . We start with the Affymetrix gene expression CCLE dataset and then apply single-sample GSEA 8 using a gene set containing 386 NRF2-driven genes 18 . This gene set NFE2L2.V2 is available in the Molecular Signatures Database v4.0 MSigDB, http://www.broadinstitute.org/gsea/msigdb. The additional target dataset consists of the similarly computed per-sample NRF2 enrichment profiles for each 153 of primary lung adenocarcinomas and squamous lung tumors from The Cancer Genome Atlas (TCGA) dataset 26 . npg Example 3. As the target, we use the MEK-inhibitor PD-0325901 sensitivity profile in 493 cancer cell lines from the Broad Novartis CCLE 14 . The sensitivity assay was performed as part of a high throughput screen at the Genomics Institute of the Novartis Research Foundation. Cell-compound mixtures were incubated for 72-84 h and cell numbers were estimated by measuring the amount of ATP per well using Cell Titer Glo (Promega). The drug-response data was fitted to a four-parameter sigmoid model (for additional details see ref. 14) .
Example 4. The KRAS-dependency profiles corresponds to the feature 'KRAS_1_001111101011' from a subset of 100 cell lines (excluding hematopoietic cell lines) from the Achilles project dataset 9 (Achilles_102lines_gene_ solutions.gct) release 2.0 available at http://www.broadinstitute.org/achilles. The per gene essentiality profiles are provided as part of the official Achilles release and obtained using the ATARiS algorithm 30 .
Running REVEALER: relevant factors to consider. When running REVEALER, there are a number of considerations that deserve further discussion because of their importance in making optimal use of the method. In this section we review those.
Choice of target profile. As this is a critical choice to make the application of REVEALER successful, it is best to use direct readouts that delineate the 'active' or 'sensitive' states of interest as in the four examples shown above. Ideally, these are profiles that have been well characterized or validated, and if a known associated genomic feature explains a number of the samples in the target profile (for example, KRAS mutations with KRAS dependency), this not only serves as an assurance that the target profile is a good representation of the phenotype of interest, but can also subsequently be used as a strong input seed feature.
Analysis of alternative features. In its standard modality of use, described in the examples above, REVEALER chooses the best match based on the absolute IC score at each iteration. However, inspection of the list of additional features may reveal other potentially interesting features. For example, in the MEKinhibitor example, in the first 3 iterations of REVEALER runs ( Supplementary  Figs. 6-8) , we can see that in addition to the top hits, REVEALER finds amplifications in chr13q11-32, a region that was found to also associate with the βcatenin activation profile in Example 1 (ref. 16 ). This may suggest a potentially alternative and interesting relationship between a component of the WNT and the MAPK pathway 60 .
Validating REVEALER results. It is often desirable to validate REVEALER's results on independent target and features datasets to confirm if the findings generalize. We were able to independently validate these results as illustrated in example 1 with an shRNA dataset ( Fig. 2b) and in example 2 using a lung tumor dataset ( Supplementary Fig. 5 ). It is also highly advisable to follow up on REVEALER findings with experimental confirmation as illustrated in example 2 (Fig. 3b) and Example 4 ( Fig. 5d,e) .
Choosing a seed and its influence on Revealer. Because REVEALER implements a sequential search starting with the seed, it is preferable to choose a seed that represents an established association. Typical examples of seeds are: mutations or amplification of oncogenes but other potential choices are: epigenetic modifications, fusion products, effector proteins, loss of tumor suppressors, etc. Utilizing seeds with strong established relationships with the target profile can provide substantial power in identifying additional, alternative causal events underlying activation, sensitivity or dependency of the target. REVEALER can also be run in the absence of a seed if none is known (that is, null seed in example 3). To investigate the influence of seeds on results from REVEALER, we reran examples 1, 2 and 4 described above with a null need. In example 1, REVEALER finds the same results as in the original run with the seed (Table 1 and Supplementary Fig. 15a ) likely as a consequence of the strength, complementarity and high target coverage of those sets of features. In example 2, REVEAER finds KEAP1 and the amplicon in 15q26.3 as in the original example, but instead of finding the NRF2 mutations or amplifications, which were the original seed, it finds a deletion in 2p21.2. In example 4 where the target is KRAS essentiality, mutations in KRAS G12-13 are found as the first feature but the subsequent features are different than when running using the seed.
Robustness of REVEALER results. Here are the results of performing a subsampling procedure for the first example (β-catenin) where we chose 80% of the samples at random and then re-run REVEALER ten times: CTNNB1.MC_MUT ARFGEF1_MUT 8q13 LGR5_MUT 12q22-q23, and CTNNB1.MC_MUT ITGBL1_AMP 13q33 DLG2_AMP 11q21. The results of this benchmark suggest that REVEALER's results are reasonably reproducible unless the input dataset is too small, the seed is too sparse, or there is no significant association between target and features.
Complementary clustering of abnormalities at every REVEALER iteration. REVEALER shows the top scoring abnormalities based on the CIC in decreasing order at every iteration. For example, in Supplementary Figure 1a we can see the top scoring abnormalities at iteration 1 of example 1 (β-catenin activation). It is clear from this figure that there are some abnormalities that share the same pattern and it is useful for REVEALER to cluster them in groups. Supplementary Figure 1b shows the results of this clustering where the abnormalities have been grouped in several distinct groups. It is much easier to recognize the different patterns once they have been clustered. This allows the user to identify other potential hits besides the top scoring one. The clustering is accomplished by performing a non-negative matrix factorization of the patterns of the n (user-selected) top-scoring abnormalities at every iteration following the model selection method we introduced in references 61,62 . REVEALER performs multiple runs at every value of k, the number of clusters, compiles statistics and determines the optimal value of k using the cophenetic coefficient 61 .
Example 2 NRF2 dual luciferase assay. Dual luciferase assay was carried out by using antioxidant response reporter (ARE) obtained from Qiagen. All open-reading frame (ORF) constructs were generated in plx304 gateway vector systems. NOX5 construct was generated using gateway cloning system using template ORF obtained from Origene (RC230463). 293T cells were seed at a density of 8,000 cells in a 96 well format. 293T cells were cultured in Dulbecco's modified eagle medium (DMEM Life Technologies) supplemented with 10% Fetal Bovine Serum (FBS). 24 h after cells were seeded, respective ORF constructs (0.1 µg) were co-transfected with ARE reporter construct (0.1 µg). All transfections were carried out using TransIT-LT1 transfection reagent from Mirus bio (Mirus bio LLC). All transfections were done in triplicates. 24 h post-transfection. Luciferase assay was carried out using a dual luciferase reporter assay (Promega) in a 96-well format following manufacturer's protocol. Relative luciferase activity was calculated as the ratio of firefly luciferase to Renilla luciferase activity as an internal control for transfection efficiency. All assays were carried in triplicates as three independent experiments. Example 4 KRAS dependence assay. The cancer cell lines A549, NCI-H2009, NCI-H1944, NCI-H1792, NCI-H2110, NCI-H1781, NCI-H1648, NCI-H2126, NCI-H2342, NCI-H28, NCI-H1437, NCI-H2228 were cultured in RPMI supplemented with 10% FBS. 293T cells were grown in DMEM supplemented with 10% FBS. Lentiviruses were produced by transfection of 293T cells with vectors encoding shRNAs (1 µg) together with the packaging plasmids encoding D8.9 and VSV-G using Fugene 6 (Roche). Culture supernatants containing lentivirus were collected 48 h after transfection. Cells were infected in 8 µg µl −1 polybrene containing media using a 1:5-1:20 dilutions of virus. After centrifugation at 1,000g for 15 min, all NSCLC lines were selected in puromycin starting 24 h after infection. Relative viability was assessed 7 d after infection using CellTiter-Glo assay according to manufacturer's protocols (Promega). Lentiviral vectors encoding shRNAs for KRAS were obtained from the Broad Institute RNAi Consortium (TRC) (TRCN0000033263, TRCN0000033260).
Running the examples with no seed and with ElasticNet and Dendrix.
To compare the results sets across methods, we chose to focus on the same number of results as produced by REVEALER as these other methods produced a long list of output features and require the user to decide how many to consider. As it is difficult to know what are the complete and biologically correct results for each of the examples, and in addition, each method has multiple parameters npg that can be tuned in different ways, it is not possible to assess the effectiveness of each method unequivocally or with absolute certainty.
To run the ElasticNet 34 we use the pensim 1.2.9 R package using the function opt2D with L1 range = (0.1, 1) and L2 range=(20, 1,000) with fold=5 (example 1 and 4) or 2 (examples 2 and 3) and L1 and L2 gridsize = 5 (example 1 and 4) or 3 (examples 2 and 3). The "response" input variable is the target profile and the "penalized" input array is the transposed of the features matrix.
To run Dendrix 38 we use version 0.3 (Feb. 4, 2013) with the following parameters: mutations_file = formatted features matrix, minFreqGene = 3, K = 3 (for examples 1-3) and 4 (for example 4), number_iterations = 2,000,000, analyzed_genes_file=file with gene list, num_exper=15, step_length=10,000. As Dendrix does not take an input profile we restricted the analysis to the subset of the most 'active' input samples, that is, those with values that account for the upper 1/3 of the target distribution in examples 1 and 2, and all samples with MEK-inhibition, or KRAS essentiality, below the mean in examples 3 and 4, as in this case lower values imply higher sensitivity or essentiality. Once the Dendrix 15 output files are produced we read them and create a table summarizing the accumulated weight for each set of features across output files and finally sort them in decreasing order. We select as the final result the feature set with the highest weight and list it in Table 1 for each example.
Simulated data benchmarks: REVEALER using information-and correlation-based metrics, ElasticNet and mRMR.
This benchmarks allows us to generate and explore in a systematic way a large number of REVELER iteration instances. This is useful to better understand the properties of the algorithm in controlled circumstances and to make a systematic comparison, for example, of the use of information-and correlation-based association metrics. We generated 5,000 simulated data instances of target, seed, complementary-feature (the signal) and a set of 2,000 random features (the noise). To make these instances reflect the structure of the real data we generated them using skew-t distributions fitted to the real data. We borrowed this analysis methodology from another project where it was developed in a more general feature selection context (R. Rangan, A. Aguirre, J.W. Kim, W. Hahn, J.P. Mesirov and P. Tamayo, unpublished data) . In what follows we will describe the specific tailored methodology that is relevant to the REVEALER benchmarks. Notice that this procedure to generate simulated data has no relation at all with the REVEALER algorithm.
Simulated target generation. The challenge to generate simulated target profiles is that these often display asymmetric behavior with distributions that have slowly decaying tails representing extreme values, typically associated with the biologically active or dependent state of the target profile. We found that asymmetric skew-t distributions 63, 64 , which are parameterized by four parameters (location ∝, scale σ, shape α and degrees of freedom ν), provide a reasonable model to fit and represent those empirical distributions. Supplementary Figure 13 shows the result of fitting skew-t distributions to the targets for the two REVEALER examples for which we have the larger number of samples (examples 2 and 4). These models will allow us to generate simulated data with the same degree of asymmetry and long tail behavior as the real data. For our purposes the most important parameters are the shape, which controls the degree of asymmetry of the distribution, and the degrees of freedom that control the decay of the tails. The fitted shape and degrees of freedom parameters for those two distributions indicate a far amount of skewness and departure from Gaussian behavior. To generate simulated targets for our benchmark we will draw random samples from a skew-t distribution with zero central location, scale set to one, and shape and degrees of freedom parameters chosen at random but centered on the values for example 2 (α II = 3.99, ν II = 5.57). To generate the instances we set the number of samples to N = 200 and repeat the following procedure.
Repeat 5,000 times (i = 1, …, 5000):
• Sample randomly the value of the shape parameter (α i ) from a normal distribution centered at example 2's shape parameter (α II = 3.99) and with standard deviation ¼ of that value: ∝ ∼ = ( , , , ). 0 1 a n Notice we set the location and scale parameters to 0 and 1 respectively to generate normalized values.
Each of the generated profiles will be used as a hypothetical target in the benchmark. One example of those target profiles is shown at the top of Supplementary Figure 14a .
Generating simulated seed and complementary feature. For each target profile generated as described above we generate a matching seed and complementary-feature. These two have to complement each other but also have to be correlated with the target. To accomplish this first we estimate the probability of activation of the target using its skew-t distribution. Then we generate a binary proto-seed correlated with the degree of activation of the target (see below). Finally, the proto-seed is split into seed and complementary feature parts and independent noise is added to both.
For each target instance generated above perform this procedure:
• Estimate the degree of activation (probability) PA(t) of the target t for each sample (green line in Supplementary Fig. 14A ) using the log ratio of the skew-t distribution used to generate the target P(t) (blue line in Supplementary  Fig. 14) and its reflected distribution P′(t) about the peak (dotted red line in Supplementary Fig. 14) .
PA t P t P t P t P t dt
This approach assumes that the higher the PA value, the higher the probability that the seed and complementary variables would be active; that is, present in their "altered" states. Using the PA values we then create a binary proto-seed feature x k by drawing a Bernoulli binary variable with probability proportional to the degree of activation of the target. We repeat this procedure until the number of alterations is equal to a pre-determined number (drawn from a normal distribution centered at 1/8 of the number of samples with 1/50 of the number of samples as standard deviation). • Generate the seed and the complementary feature by randomly splitting the proto-seed into seed and complementary-feature parts with the fraction of split chosen at random uniformly from 0.3 to 0.7. • Add to the seed and complementary feature random binary noise with a frequency chosen uniformly between 0 and 5%.
This process generates realistic triplets of target, seed and complementary feature as can be seen in Supplementary Figure 14b . The remaining task to complete the instance generation is to create a set of random features, which npg will compete with the complementary feature, the signal, as potential matches to the target conditional on the seed.
Generating random features. To generate the random features we also use a skew-t distribution but in this case a different one to represent the number of genomic alterations, for example mutations or copy number alterations of a given frequency, in the input feature dataset. To accomplish this we fit a skew-t distribution to the histogram of genomic alteration frequencies in the REVEALER input feature dataset as show in Supplementary Figure 14c . The fit of the data to the skew-t distribution is quite good. We generate random features by first drawing the number of altered samples from the fitted skew-t distribution of Supplementary Figure 14c , and then by generating a random vector with that many alterations. This is repeated for a total of 2,000 independent random features. Once the random features are generated the complementary feature generated above is added to the random features to complete the formation of a simulated feature set for each iteration instance of the benchmark. Supplementary Figure 14b shows four examples of simulated iteration instances including the best of the random features from a total of 2,000 random features.
Benchmark results analysis. The first aspect of the benchmark results we analyzed was the degree of variation of IC and CIC values generated by the 5,000 instances. For each instance, as it is done by REVEALER in a real data iteration of the algorithm, we estimate the Information Coefficient (IC) between the target and the seed, and the Conditional Information Coefficient (CIC), of each feature in the input dataset conditional on the seed. These quantities for the examples in Supplementary Figure 14b are shown on the right side of the each heatmap. Supplementary Figure 14d shows these quantities for each of the generated instances where the IC is plotted in the x-axis and the CIC in the y-axis. We can see that the simulated data generation process indeed covers a wide range of values for the IC and the CIC. The observed values, from about 0.1 (very low association) to about 0.6 (very high association), encompass all the IC and CIC values seen in the actual REVEALER examples' iterations and gives us confidence that the benchmark instances effectively cover realistic dynamic range values for the IC and the CIC.
For each of the simulated instances we actually know if the algorithm choses the right feature, that is, the explicitly generated complementary feature, instead of one of the random ones. This choice will depends on which CIC value is higher: the one of the complementary feature or the one of the best random feature. Based on this knowledge we can label each instance as one where the algorithm got it right or where it was fooled and choose a random feature instead (Supplementary Fig. 14d ). For the specific settings of the benchmark, REVEALER gets the right answer 68.62% of the time. This value is obviously dependent on the specific parameters we choose for the benchmark. As can be seen in Supplementary Figure 14d , it appears that REVEALER can identify the complementary feature reasonably well where its conditional mutual information (CIC) is roughly above 0.30 for a wide rage of IC values between the target and the seed. To better determine the exact value of the CIC where the algorithm has probability 0.50 of extracting the signal (complementary feature) from the noise (best random feature), we fit a logistic model and obtained the curve shown in Supplementary Figure 14e . The relevant 50% probability threshold CIC value is 0.315. Interestingly there is a sharp transition around that point in terms of how quickly the probability of finding the signal decreases for values below that threshold, and how quickly it increases for CIC values above.
We also repeated the same benchmark but instead of the IC/CIC information-based metrics we use the correlation and the partial correlation (COR/ PCOR; "ppcor" R package). This is interesting because one could imagine running REVEALER using the faster more traditional correlation-based metrics. The right side of Supplementary Figure 14d shows the results of using correlation-based metrics on the same benchmark instances. One can see that they display a larger spread of values and get the right answer only 50% of the time. This lower performance with respect to information-based metrics (which achieve 68.62%) seems to imply that the information-based metrics are more sensitive and have better discriminatory power than the correlation-based ones. To study this further we defined a "signal to noise" ratio equal to the CIC of the complementary feature divided by the CIC of the best random feature and the corresponding quantity for the correlationbased metrics (Supplementary Fig. 14f ). In this figure, the green dots correspond to instances in which both metrics find the right feature (signal to noise ratios greater than 1). The red dots correspond to cases where both fail (signal to noise ratios less than 1). The blue dots on the upper left quadrant correspond to cases where the information-based metrics win and the correlation-based loose, and purple vice versa. Then the proportion of blue to purple instances will quantify the differences between using the information-and correlation-based metrics on the same data. This proportion is about 8.6 and provides again compelling evidence for the higher sensitivity of information over correlation-based metrics. Another alternative way to look at these results is by generating ROC curves. This is shown in Figure 6a where the information-based metrics attain a better area under the curve (0.872) compared with the correlation-based ones (0.674).
These results were obtained with the specific parameters we choose to run the benchmark but the overall picture is similar if we run with somewhat different but still realistic values. In contrast, if we make the skew-t distributions much less skewed and much more Gaussian-like, the association of the target against the seed and complementary features become more linear and the differences between information-and correlation-based metrics diminishes as expected. In the limit of perfectly linear associations the mutual information is equivalent to the correlation 50, 54 . However, the real data is clearly non-Gaussian and non-linear.
These results indicate that the correlation-based-metrics have less sensitivity than the information-based metrics. This lack of sensitivity associated with correlation-based metrics is also an effect that can be observed in actual runs of REVEALER. For example if we re-run the REVEALER examples using correlation/partial correlation, instead of the original mutual information metrics; we can reproduce the 1st iteration hits but frequently found differences in subsequent iterations. For instance, in the second iteration of the β-catenin example the partial correlation selects the entire chr 13 instead of the narrower and more precise chr 13q33. Chr 13 is indeed a matching pattern to the target profile but not as good as chr 13q33 to explain additional samples. Similarly, in the NRF2 example both information and correlation-based metrics select KEAP1 mutation as the top first iteration hit; however, in the 2nd iteration the partial correlation gives a higher score to Xq21.3 than the original choice of 15q26.3. Again in this case 15q26.3 is a better match and also one that we know to be correct based on our experimental validation. These few examples, plus the results of the simulated benchmarks describe above, give compelling evidence that the correlation works well for strong features but lacks enough sensitivity to discriminate between subtler non-linear relationships as often encounters in subsequent iterations. This can be explained in part by the theoretical advantages of the mutual information in terms of detecting non-linear associations 47, 48, 50, 54 .
We also ran the same benchmark but using ElasticNet 34 and mRMR 35 methods as implemented in the pensim 1.2.9 (ref. 43) and mRMRe 2.0.5 (ref. 65) R packages. We consider only the top two highest-scoring features identified by these methods and perform 300 instances because of the time it takes to perform the computation. For the opt2D function we use the same parameters as described in 6 above. The ROC curves displaying the results are shown for two modalities: i the benchmark is restricted to instances where these methods find the seed as one of the two top features (Fig. 6a) , and ii regardless of the seed being identified as one of the two top features (Supplementary Fig. 15e ).
